Roche Pharmaceutical Development and Sales Overview

Crovalimab (RG6107, SKY59) A humanized monoclonal antibody against complement C5 Indication Sickle cell disease (SCD) acute treatment Sickle cell disease (SCD) chronic VOC prevention Phase/study # of patients Design Phase Ib CROSSWALK-a N=30 ■ ARM A: Crovalimab ARM B: Placebo " Primary endpoint Safety FPI Q1 2022 Status CT Identifier SCD-Sickle Cell Disease; VOC-Vaso-occlusive crises NCT04912869 Phase lla CROSSWALK-C N=90 ■ ARM A: Crovalimab ARM B: Placebo ■ VOC rate, up to 48 weeks FPI Q1 2022 NCT05075824 120 Roche Immunology

View entire presentation